Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Strategic Projects - Group

Queen's University

$188,510.00

N-acylated hexosamines as nutraceuticals : from shellfish to algae to mammalian bone and joint health

EF 2010-11

Résumé
Glucosamine (GlcN) is used extensively as an ""over the counter"" preparation for joint and bone disorders. However, it is not clear from clinical trials that it actually works. The main source GlcN is chitosan, which is derived from chitin, the most abundant polymer in the animal kingdom. So GlcN is a ""nutraceutical"". We have developed a series N-acylated glucosamines (GlcNAcyls), which are chemically modified nutriceuticals, for veterinary and human applications, primarily in arthritis and osteoporosis. Our preferred (lead) compound, N-butyryl glucosamine (GlcNBu) has shown positive effects in animal models for these applications, GlcN itself has not. Other applications, for which we have preliminary data, include enhancing animal growth and weight gain and possibly cognition and increased mobility in aged dogs. GlcNBu appears to have very little, if any, toxicity. Patents for the above applications have been issued in conjunction with the Canadian Arthritis Network, which is a National Centre of Excellence. Initially we will extend our studies on the mammalian applications. We will then study the possible mechanisms of action of GlcNBu and other GlcNAcs to account for the effects we see in animals. We will also investigate biological synthetic approaches, involving an important intermediary compound called butyryl Co-enzyme A, exists in mammals as well as in bacteria and algae. We will focus on the bacteria and common algae, since butyrly Co-enzyme A is known to be important in some types of bacteria and probably algae. Ultimately, we anticipate being able to apply biologic ""green technologies"" for the commercial synthesis of GlcNAcyls, utilizing bacterial or algae factories. Algae would be particularly attractive as they easily grow in water. Production of GlcNAcyls by bacteria or algae could have significant postive effects for the Canadian economy. Canadian supporting organizations include: CanCog (Toronto), Bioniche (Belleville) and Kingfisher International Inc (Stouffville). The project will train a signifcant number of Highly qualified personnel,
Programme
Strategic Projects - Group
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
381564-2009
Name nom
Anastassiades, Tassos
Department département
Biochemistry
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2009
Award amount
188510
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1044
Committee name en
Strategic Projects Selection Panel - Food and Bioproducts
Committee name fr
Comité de sélection des projets stratégiques - Aliments et bioproduits
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Partie
2
Nb partie
3
Application title
N-acylated hexosamines as nutraceuticals : from shellfish to algae to mammalian bone and joint health
Keyword
NSERC
Application summary
Glucosamine (GlcN) is used extensively as an ""over the counter"" preparation for joint and bone disorders. However, it is not clear from clinical trials that it actually works. The main source GlcN is chitosan, which is derived from chitin, the most abundant polymer in the animal kingdom. So GlcN is a ""nutraceutical"". We have developed a series N-acylated glucosamines (GlcNAcyls), which are chemically modified nutriceuticals, for veterinary and human applications, primarily in arthritis and osteoporosis. Our preferred (lead) compound, N-butyryl glucosamine (GlcNBu) has shown positive effects in animal models for these applications, GlcN itself has not. Other applications, for which we have preliminary data, include enhancing animal growth and weight gain and possibly cognition and increased mobility in aged dogs. GlcNBu appears to have very little, if any, toxicity. Patents for the above applications have been issued in conjunction with the Canadian Arthritis Network, which is a National Centre of Excellence. Initially we will extend our studies on the mammalian applications. We will then study the possible mechanisms of action of GlcNBu and other GlcNAcs to account for the effects we see in animals. We will also investigate biological synthetic approaches, involving an important intermediary compound called butyryl Co-enzyme A, exists in mammals as well as in bacteria and algae. We will focus on the bacteria and common algae, since butyrly Co-enzyme A is known to be important in some types of bacteria and probably algae. Ultimately, we anticipate being able to apply biologic ""green technologies"" for the commercial synthesis of GlcNAcyls, utilizing bacterial or algae factories. Algae would be particularly attractive as they easily grow in water. Production of GlcNAcyls by bacteria or algae could have significant postive effects for the Canadian economy. Canadian supporting organizations include: CanCog (Toronto), Bioniche (Belleville) and Kingfisher International Inc (Stouffville). The project will train a signifcant number of Highly qualified personnel,